All Children’s Hospital Los Angeles locations are open.
Wildfire Support Line for Current Patients, Families and Team Members:
323-361-1121 (no texts)
8 a.m. - 7 p.m.
This study is recruiting CHLA staff/employees/trainees to participate in a study assessing the efficacy of different types of video in teaching a surgical skill to novices. Participants will complete a survey and a medical training task, watch a video, and then repeat the medical training task in 2 weeks.
To find out the effects of Maralixibat on the treatment of PFIC.
To see if eye tracking (ET) or electroencephalogram (EEG) assessments have potential use in future clinical trials of Autism Spectrum Disorders (ASD).
The purpose of this study is to (1) determine the minimum effective dose of abiraterone acetate that normalizes androstenedione levels in prepubertal children with CAH secondary to 21-hydroxylase deficiency (Phase 1 trial), and (2) assess the utility of abiraterone acetate in prepubertal children with CAH as adjunctive therapy to minimize excessive androgen secretion and allow more physiological glucocorticoid replacement (Phase 2 trial).
Individuals with Down syndrome are at risk for the development of Alzheimer's disease. This study seeks to explore if neurodegenerative biomarkers of this condition are present in childhood. In addition, this study will explore the possibility of these same biomarkers being present in children with autism spectrum disorder and other neurodevelopmental conditions.
This is a Phase 1/2, first-in-human, open-label, dose-escalation study designed to evaluate the safety, tolerability, and efficacy of BBP-631 administered to up to 25 adult participants diagnosed with classic congenital adrenal hyperplasia (CAH) (simple virilizing or salt-wasting, Group 1) or with classic salt-wasting CAH (Group 2) due to 21-hydroxylase deficiency (21-OHD) and who are monitored for 24 weeks post-treatment. All participants who receive BBP-631 will be followed for an additional 4.5 years for safety and efficacy in a separate long term follow up protocol (Study CAH-399). In total, all participants will be followed for at least 5 years after the date of treatment with BBP-631.
The goal of this study is to help researchers across the nation develop and tailor healthcare treatments to the individual. They will do this by collecting data & biospecimens that may enable a broad spectrum of research studies.
To test the effectiveness of an addiction-based weight loss intervention, embodied first as a smartphone app with telephone coaching (AppCoach) compared to (1) addiction model based weight-loss app alone (App) and (2) multi-disciplinary in-clinic weight loss intervention (Clinic) on weight outcomes of overweight and obese adolescents at 3, 6, 12 and 18 months post enrollment.
This prospective, longitudinal study aims to measure and describe the amount and frequency of physical activity, feeding, and sleeping across days and months in infancy.
The purpose of this study is to evaluate a sensor that transmits intracranial pressure, cerebrospinal fluid flow, and makes sure the path of the catheter remains open.